Why WGS-HiFi is Transforming Newborn Screening
Traditional newborn screening detects only a limited number of disorders, leaving many rare genetic diseases undiagnosed until irreversible symptoms appear. PacBio HiFi Whole Genome Sequencing (WGS-HiFi) overcomes this limitation through highly accurate long-read sequencing, enabling simultaneous detection of SNVs, indels, structural variants, repeat expansions, and methylation signatures from a single test. Its superior ability to resolve complex genomic regions and phase disease-causing variants makes it highly effective for early rare disease diagnosis in newborns.
Clinical & Translational Significance
Early genomic diagnosis enables timely therapeutic intervention before disease progression, significantly improving survival and long-term outcomes. WGS-HiFi is particularly valuable for disorders such as SMA, Pompe disease, lysosomal storage disorders, OTC deficiency, and repeat expansion disorders, where rapid detection can enable immediate treatment initiation. Emerging large-scale initiatives, including Thailand’s population-wide HiFi newborn screening program, highlight the growing global adoption of genomic newborn screening strategies.
WGS-HiFi Newborn Screening Workflow
Newborn Sampling → DNA Isolation → PacBio HiFi WGS → Long-Read Variant Detection → Integrated Clinical Interpretation → Rare Disease Identification → Early Therapeutic Decision Support
WGS-HiFi Sequencing
- PacBio HiFi long-read sequencing
- High-accuracy whole genome profiling
- Detection of SNVs | SVs | repeats
- Improved resolution of complex regions
Computational & Integrative Analysis
- Variant calling & phasing analysis
- Structural variant identification
- Rare disease variant prioritization
- Clinical interpretation for precision newborn care
Key Scientific Takeaway
Leveraging advanced PacBio HiFi WGS analytics, long-read variant interpretation, and clinical-grade bioinformatics pipelines, Nucleome Informatics played a key role in transforming complex genomic datasets into clinically actionable rare disease insights. Through integrated analysis of SNVs, structural variants, repeat expansions, phasing patterns, and difficult-to-map genomic regions, Nucleome enabled high-confidence identification of pathogenic alterations associated with inherited pediatric disorders.
With expertise in multi-omics interpretation, AI-assisted variant prioritization, translational genomics, and precision diagnostics, Nucleome is well-positioned to support future large-scale newborn screening and rare disease initiatives by accelerating biomarker discovery, improving diagnostic yield, and enabling scalable precision medicine frameworks for next-generation clinical genomics.
Leave a Reply